When high dimensional single-cell technologies propel translational research from bench to bedside

Cutaneous squamous cell carcinomas (cSCC) are the 2nd deadliest skin cancer. They are currently treated by excisional surgery but can reach, for some patients, a non-operable stage associated with rapid local and nodal relapses and a very poor prognosis. However, no consensus has been reached on the clinical or molecular factors predicting these recurrences. It is therefore crucial to improve the identification of patients that would relapse by the characterization of prognostic biomarkers. An integrative spatial characterization of cSCC immune microenvironment and the interactions of their components are required to identify such biomarkers.

More information (Summary and biography)